Exagamglogene autotemcel (Casgevy)
Gene therapy / editing
Also known as CTX001
Evidence outlook
Approved: Sickle Cell Disease, Transfusion-Dependent Beta Thalassemia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signalSingle-arm, accepted for approval (FDA label)
Also approved (2)
- Severe sickle cell disease with recurrent vaso-occlusive crises and transfusion-dependent beta thalassemia, 12 years and older (conditional marketing authorisation)
- Sickle cell disease and transfusion-dependent beta thalassemia, 12 years and older
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05329649 NCT05329649 · Sickle Cell Disease Registry: NCT05329649 | 3 | Proportion of Participants who do not Have any Severe Vaso-occlusive Crises (VOCs) for at Least 12 Consecutive Months (VF12) (Up to 24 Months After CTX001 Infusion) 2027-06-06 | In progress: results expected 6 Jun 2027 | not yet graded | link ↗ |
View 3 more trials
NCT05477563 NCT05477563 · Sickle Cell Disease Registry: NCT05477563 | 3 | Fetal Hemoglobin (HbF) Concentration Over Time (Up to 12 Months After CTX001 Infusion); Total Hemoglobin (Hb) Concentration Over Time (Up to 12 Months After CTX001 Infusion) 2027-06-09 | In progress: results expected 9 Jun 2027 | not yet graded | link ↗ |
NCT04208529 NCT04208529 · Sickle Cell Disease Registry: NCT04208529 | 3 | New malignancies (Signing of informed consent up to 15 years post CTX001 infusion); New or worsening hematologic disorders (Signing of informed consent up to 15 years post CTX001 infusion); All-cause mortality (Signing of informed consent up to 15 years post CTX001 infusion); Serious adverse events (SAEs) (Signing of informed consent up to 15 years post CTX001 infusion); CTX001-related adverse events (AEs) (Signing of informed consent up to 15 years post CTX001 infusion) 2039-09-30 | In progress: results expected 30 Sept 2039 | not yet graded | link ↗ |
NCT03745287 NCT03745287 · Sickle Cell Disease The study was open-label, nonrandomized, and single-arm, with 46 participants receiving exagamglogene autotemcel and no placebo or active comparator. Although the primary clinical outcome was favorable, reporting a response in an uncontrolled study cannot establish comparative treatment benefit, so the evidence is graded weak. Registry: NCT03745287 | 2/3 | Percentage of Participants Who Have Not Experienced Any Severe Vaso-occlusive Crisis (VOC) for at Least 12 Consecutive Months (VF12) After Exa-cel Infusion (From 60 days after last RBC transfusion up to 2 years after exa-cel infusion); Percentage of Participants Who Achieve Neutrophil Engraftment (Up to 24 months post exa-cel infusion.); Time to Neutrophil Engraftment for Participants Who Achieve Neutrophil Engraftment (Up to 24 months post exa-cel infusion.); Time to Platelet Engraftment for Participants Who Achieve Platelet Engraftment (From Exa-cel infusion up to 2 years after exa-cel infusion); Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (From receiving exa-cel infusion up to 2 years); Transplant-related Mortality (TRM) Within 100 Days After Exa-cel Infusion; Transplant-related Mortality Within 12 Months Post Exa-cel Infusion; All-cause Mortality (From exa-cel infusion up to 2 years) 2025-07-07 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Sickle Cell Disease: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Exagamglogene Autotemcel (Casgevy): this drug | Approved | Gene therapy / editing | BCL11A erythroid enhancer (gene editing) | Weak signal | No reviewed efficacy summary in this indication | |
| Crizanlizumab-Tmca (Adakveo) | Approved | Monoclonal antibody | P-selectin | Partial signal | Featured results are non-efficacy only in this race | |
| Hydroxyurea (Droxia) | Approved | Small molecule | Ribonucleotide reductase | not yet graded | No reviewed efficacy summary in this indication | |
| Hydroxyurea (Siklos) | Approved | Small molecule | Ribonucleotide reductase | not yet graded | No reviewed efficacy summary in this indication | |
| Hydroxyurea (Xromi) | Approved | Small molecule | Ribonucleotide reductase | Weak signal | No reviewed efficacy summary in this indication | |
| L-Glutamine (Endari) | Approved | Small molecule | Amino Acid | Reliable signal | NCT01179217: The Number of Occurrences of Sickle Cell Crises (48 weeks): L-glutamine 3 Number of crises (range 0 to 15) | 100% Maltodextrin 4 Number of crises (range 0 to 15) | |
| Lovotibeglogene Autotemcel (Lyfgenia) | Approved | Gene therapy / editing | Beta-globin gene addition (betaA-T87Q) | not yet graded | No reviewed efficacy summary in this indication | |
| Etavopivat | Phase 3 | — | Pyruvate kinase | not yet graded | No reviewed efficacy summary in this indication | |
| Mitapivat (Pyrukynd) | Phase 3 | Small molecule | Pyruvate kinase | not yet graded | No reviewed efficacy summary in this indication | |
| Decitabine / Tetrahydrouridine (NDec) | Phase 2 | Small molecule | DNMT1 (DNA methyltransferase 1) | not yet graded | No reviewed efficacy summary in this indication | |
| HBI-002 | Phase 2 | Small molecule | Carbon monoxide (CO)-based gas therapeutic; oral liquid CO formulation | not yet graded | No reviewed efficacy summary in this indication | |
| ITU512 | Phase 1/2 | Small molecule | WIZ transcription factor | not yet graded | No reviewed efficacy summary in this indication | |
| Nula-Cel | Phase 1/2 | Gene or cell therapy (subtype unspecified) | HBB gene (sickle mutation correction) | not yet graded | No reviewed efficacy summary in this indication | |
| Ristoglogene Autogetemcel | Phase 1/2 | Gene therapy / editing | HBG1/HBG2 promoters | not yet graded | No reviewed efficacy summary in this indication | |
| DISC-3405 | Phase 1 | Monoclonal antibody | TMPRSS6 (matriptase-2) | not yet graded | No reviewed efficacy summary in this indication | |
| SCD-101 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| VAS-101 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| Iloprost (Ventavis) | Discontinued | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Renizgamglogene Autogedtemcel | Discontinued | Gene or cell therapy (subtype unspecified) | HBG1/HBG2 promoters | not yet graded | No reviewed efficacy summary in this indication | |
| Voxelotor (Oxbryta) | Discontinued | Small molecule | Hemoglobin S (HbS) | Reliable signal | NCT03036813: Haemoglobin response (>1 g/dL rise at week 24): voxelotor 1500 mg 46/90, 900 mg 30/92, placebo 6/92 |
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Exagamglogene autotemcel (Casgevy) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (4)
June 2027 (2)
October 2027 (1)
What to watch
November 2027 (1)
What to watch
2028 (1)
May 2028 (1)
What to watch
2039 (1)
September 2039 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent